Back to Results

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy

Interested in this Trial?

Contact Us

Trial Status Enrolling By Invitation

Trial Identifier

NCT07573631

Condition

Duchene Muscular Dystrophy

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This open-label extension study aims to evaluate the long-term safety and tolerability of weekly BMN 351 infusions, as well as to assess the effect of BMN 351 on physical function, in participants with DMD who participated in the 351-201 study.

Eligibility Criteria

Birth Sex

Male

Age

From 4 Years

Healthy Volunteers

No

Drug/Treatment:

BMN 351

Phase:

Phase 2

Study Type:

Interventional

Number of Participants:

18

Study Started:

2026-04

Study Updated:

2026-05-07

Trial Locations

  • Fondazione Serena ETS - Centro Clinico NeMO Milano

    Milan, Italy

  • UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Italy

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Hospital Viamed Santa Angela De la Cruz

    Seville, Spain

  • Yeditepe University Kosuyolu Hospital

    Istanbul, Turkey, Turkey (Türkiye)

  • Great Ormond Street Hospital NHS Foundation Trust

    London, United Kingdom

Inclusion Criteria

  • Participants must have completed 351-201 without permanent discontinuation of the investigational medicinal product (IMP) or withdrawal from the study
  • Currently receiving treatment with oral corticosteroids, on a stable dose regimen during 351-201, and must remain on a consistent dose regimen throughout 351-202 or 351-203 except for modifications to accommodate changes in weight
  • Transition to the equivalent dose of vamorolone is permitted in 351-202 where approved in participating countries.
  • Willing and able to adhere to the study visit schedule and other protocol requirements
  • Willing to use contraception (sexually mature males) throughout the study and for 90 days after the final dose, if sexually active
  • Contraceptive use by males should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Willing and able to provide written assent (if required by local regulations or the IRB/IEC) after the nature of the study has been explained and prior to performance of any research-related procedure
  • Willing and able to provide written, signed informed consent as parent or guardian after the nature of the study has been explained and prior to performance of any research-related procedure

Exclusion Criteria

  • Have known coagulation disorder
  • Are taking any prohibited medications
  • any approved exon skipping therapy within 12 weeks prior to baseline or with any gene therapy for the treatment of DMD at any time
  • anti-coagulants, anti-thrombotics, or anti-platelet agents
  • immunosuppressants

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us